Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.63 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3554662 | 0.99 | DPP4 (0.65) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL3555458 | 0.87 | DPP4 (0.48) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| Hydrochloric Acid SCHEMBL1222945 | 0.85 | DPP4 (0.65) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL1222488 | 0.84 | DPP4 (0.67) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL878101 | 0.81 | DPP4 (0.75) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL878100 | 0.81 | DPP4 (0.75) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL555788 | 0.80 | DPP4 (0.75) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| Hydrochloric Acid SCHEMBL3554657 | 0.80 | DPP4 (0.74) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| Hydrochloric Acid SCHEMBL3554659 | 0.80 | DPP4 (0.74) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL555644 | 0.80 | DPP4 (0.71) | DPP4CHRM1CHRM2CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | claimed |
| EP-3323818-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-05-23 | — | — | EP | claimed |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | claimed |
| US-20140051714-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | claimed |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | claimed |
| US-20140038889-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-06 | — | — | US | claimed |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | claimed |
| WO-2013055910-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | WO | claimed |
| EP-2556056-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2013-02-13 | — | — | EP | claimed |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | claimed |
| WO-2012135570-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | WO | claimed |
| WO-2011127051-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | claimed |
| US-20210340133-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10463676-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | ARENA PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190275055-A1 | Modified-Release Dosage Forms of 5-Ht2c Agonists Useful for Weight Management | ARENA PHARMACEUTICALS, INC. | 2019-09-12 | — | — | US | disclosed |
| WO-2011127051-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011005929-A1 | PIPERIDINE DERIVATIVE AND ITS USE FOR THE TREATMENT OF DIABETS AND OBESITY | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-7838528-B2 | Substituted bicyclic 8-pyrrolidinoxanthines, methods for their production, pharmaceutical formulations and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-20070167468-A1 | SUBSTITUTED BICYCLIC 8-PYRR0LIDINOXANTHINES, METHODS FOR THEIR PRODUCTION, PHARMACEUTICAL FORMULATIONS AND THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167468-A1 | SUBSTITUTED BICYCLIC 8-PYRR0LIDINOXANTHINES, METHODS FOR THEIR PRODUCTION, PHARMACEUTICAL FORMULATIONS AND THEIR USE | GPR119, INSR, GCKR | DPP4 568/4885CHRM1 3987/4885CHRM2 2630/4885 |
| US-20140038889-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, DPP4 | DPP4 3/4885CHRM1 2708/4885CHRM2 2028/4885 |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A2, SLC5A1 | DPP4 10/4885CHRM1 2943/4885CHRM2 1876/4885 |
| US-10463676-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | HTR2C, HTR2A, HTR3C | DPP4 209/4885CHRM1 140/4885CHRM2 84/4885 |
| US-20210340133-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, GLP1R, SLC5A2 | DPP4 4/4885CHRM1 3597/4885CHRM2 2717/4885 |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, GLP1R, DPP4 | DPP4 3/4885CHRM1 3433/4885CHRM2 2528/4885 |
| US-20190275055-A1 | Modified-Release Dosage Forms of 5-Ht2c Agonists Useful for Weight Management | HTR2C, HTR2A, HTR3C | DPP4 209/4885CHRM1 140/4885CHRM2 84/4885 |
| US-20140051714-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, DPP4 | DPP4 3/4885CHRM1 3217/4885CHRM2 2315/4885 |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | GPR119, GLP1R, DPP9 | DPP4 5/4885CHRM1 3172/4885CHRM2 2310/4885 |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | DPP4 6/4885CHRM1 3279/4885CHRM2 1900/4885 |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GCGR, GLP1R | DPP4 9/4885CHRM1 2089/4885CHRM2 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.